CIENCIASMEDICASNEWS: septiembre 2025

Weight-loss drugs now linked to cancer protection in women, major new study reveals Women's cancers, like endometrial and ovarian, are most reduced by GLP-1 use, research finds Angelica Stabile By Angelica Stabile Fox News Published September 29, 2025 7:00am EDT https://www.foxnews.com/health/weight-loss-drugs-now-linked-cancer-protection-women-major-new-study-reveals

New type of diabetes requires its own unique treatment, researchers say By Melissa Rudy Fox News Published September 30, 2025 7:00am EDT

New type of diabetes requires its own unique treatment, researchers say Type 5 diabetes linked to malnutrition, recognized by international experts Melissa Rudy By Melissa Rudy Fox News Published September 30, 2025 7:00am EDT https://www.foxnews.com/health/new-type-diabetes-requires-its-own-type-treatment-researchers-say

Disappearing Liver Metastases: Can MRI Plus CT Detect Them? Edited by Gargi Mukherjee September 30, 2025

https://www.medscape.com/viewarticle/disappearing-liver-metastases-can-mri-plus-ct-detect-them-2025a1000q5j

Zanubrutinib Benefits BTK-Intolerant Leukemia Edited by Susan Ruel, PhD September 30, 2025

https://www.medscape.com/viewarticle/zanubrutinib-benefits-btk-intolerant-leukemia-2025a1000q6c

Navigating Myelofibrosis and Anemia: Today's Challenges, Tomorrow’s Solutions Authors: John Mascarenhas, MD; Haifa Kathrin Al-Ali, MD; Francesco Passamonti, MD; Nona C. Baker, Dip.CounsMBACP

https://www.medscape.org/viewarticle/1002681?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_250929-OUS-HONC-1002681-cta

Healing a fractured world: mRNA therapies to take centre stage? The Lancet Oncology + +... +

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00558-3/fulltext?dgcid=raven_jbs_etoc_email Oct 2025 Volume 26Number 10p1261-1392, e509-e570 The Lancet Oncology https://www.thelancet.com/journals/lanonc/issue/vol26no10/PIIS1470-2045(25)X0010-3 Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00380-8/abstract?dgcid=raven_jbs_etoc_feature_lanonc

Editorial e1654 South Asians need culturally informed NCD action The Lancet Global Health + + + +...

Medical oxygen service readiness and service coverage in seven countries in Africa and Asia: a cross-sectional survey and clinical audit https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00328-6/fulltext?dgcid=hubspot_update_feature_updatealerts_langlo&utm_campaign=update-langlo&utm_medium=email&_hsenc=p2ANqtz-8zgLCV7j2kNvJDERwNwNboVZFg9FP3TnBmZylXe_uI80kYhJpK6x6Q2CCGLV7mM2uTxrWqnchjvwErMhs4lg_20LhEzw&_hsmi=382778918&utm_content=382719812&utm_source=hs_email Breast cancer overall survival, annual risks of death, and survival gap apportionment in sub-Saharan Africa (ABC-DO): 7-year follow-up of a prospective cohort study https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00273-6/fulltext?dgcid=hubspot_update_feature_updatealerts_langlo&utm_campaign=update-langlo&utm_medium=email&_hsenc=p2ANqtz-8F8gfdJVnQHogj9c6m5H17layyxgNELmC4nxZjlIxH04hbFqx09KhUBEG3K7DGgAoGRTs2xbN64lTHZEMiqLJZVsL6vg&_hsmi=382778918&utm_content=382719812&utm_source=hs_email Effect of Brazil's national human papillomavirus vaccination programme on the incidence of cervical cancer and cervical intraepithelial neoplasia grade 3 in women aged 20–24 years: a population-based study https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00279-7/fulltext?dgcid=hubspot_update_feature_updatealerts_langlo&utm_campaign=update-langlo&utm_medium=email&_hsenc=p2ANqtz--EKWqDhdk6XMCO4OvPXo219aUbBchcTntCpgDjYceoq-m9Fk5fgW989BtxFjuYelXEezkCvRcBJ-Q1GHMxUr2qsA7CDw&_hsmi=382778918&utm_content=382719812&utm_source=hs_email Editorial e1654 South Asians need culturally informed NCD action The Lancet Global Health https://www.thelancet.com/journals/langlo/issue/vol13no10/PIIS2214-109X(25)X0010-3

lunes, 29 de septiembre de 2025

HPV Vaccine Uptake and the Autonomy Paradox Arya Anthony Kamyab, MBBS Medscape UK September 29, 2025

https://www.medscape.com/viewarticle/hpv-vaccine-uptake-and-autonomy-paradox-2025a1000pxc

Myeloma: Updated Genomic Criteria for High-Risk Cases Nancy A. Melville September 29, 2025

https://www.medscape.com/viewarticle/myeloma-updated-genomic-criteria-high-risk-cases-2025a1000pyu

Selpercatinib Linked to Long-Term Survival in Thyroid Cancer Nancy A. Melville September 29, 2025

https://www.medscape.com/viewarticle/selpercatinib-linked-long-term-survival-thyroid-cancer-2025a1000pza

High Intake of Ultraprocessed Foods Linked to Increased Risk for Colorectal Cancer Edited by Vineeta Teotia Medscape UK September 29, 2025

https://www.medscape.com/viewarticle/high-intake-ultraprocessed-foods-linked-increased-risk-2025a1000pn9

Cancer From CT Scans: What’s the Real Risk? Amy Norton September 29, 2025

https://www.medscape.com/viewarticle/cancer-ct-scans-whats-real-risk-2025a1000q01

Recognizing Subtle Disability Worsening in Multiple Sclerosis (Part 1): The Role of Smoldering Neuroinflammation Authors: Laura Airas, MD, PhD; Martina Absinta, MD, PhD; Benjamin M. Greenberg, MD, MHS

https://www.medscape.org/viewarticle/1002761_sidebar9?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_250928-1002761-ES_LANG-NEUR

Exercise capacity in RYR1-related myopathies

https://ojrd.biomedcentral.com/?utm_source=bmc_etoc&utm_medium=email&utm_campaign=CONR_13023_AWA1_GL_DTEC_054CI_TOC-250924

A European Rare Neuromuscular Diseases Registry Hub +...

A European Rare Neuromuscular Diseases Registry Hub Rare diseases are characterised by a shortage of patients and expertise. Providing the best care requires shared cross-border expertise and data exchange. A registry hub is best for bridging siloed patient information resources for rare neuromuscular diseases. https://communities.springernature.com/posts/a-european-rare-neuromuscular-diseases-registry-hub

A How-To Guide to the Use of Anti-Amyloid Therapies: Recommendations for Setting Up Your Practice Authors: Malaz Boustani, MD, MPH; Michael H. Rosenbloom, MD, FAAN

https://www.medscape.org/viewarticle/1002805_sidebar4?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_250922-1002805-ES_LANG-NEUR

Editorial Reimagining global health architecture for a sustainable future eClinicalMedicine +...

Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00360-8/fulltext?dgcid=raven_jbs_etoc_feature_eclinm Editorial Reimagining global health architecture for a sustainable future eClinicalMedicine https://www.thelancet.com/journals/eclinm/issue/vol87nonull/PIIS2589-5370(25)X0008-0

Editorial Blastocystis: the ongoing parasitological debate The Lancet Microbe +...

Association between mycophenolic acid treatment and infection with specific strains of Pneumocystis jirovecii in solid organ transplant recipients in France and Switzerland: a multicentre, retrospective, cross-sectional study https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00074-6/fulltext?dgcid=hubspot_update_feature_updatealerts_lanmic&utm_campaign=update-lanmic&utm_medium=email&_hsenc=p2ANqtz--eaubDtiDxYKp5cyGkbdHk34LrX-3lN8Ndw66FUMvllHABrXkbRJY_KEIX26wdPO4-Y9DI1PslJTYaEFGocI82FvTKOw&_hsmi=381912454&utm_content=381826388&utm_source=hs_email Editorial Blastocystis: the ongoing parasitological debate The Lancet Microbe https://www.thelancet.com/journals/lanmic/issue/vol6no9/PIIS2666-5247(25)X0009-4 Characterisation of a persistent SARS-CoV-2 infection lasting more than 750 days in a person living with HIV: a genomic analysis https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00050-3/fulltext?dgcid=hubspot_update_feature_updatealerts_lanmic&utm_campaign=update-lanmic&utm_medium=email&_hsenc=p2ANqtz-9mf_UK7msVR8r4XTdx4d-RcBHz5GDtpjHWL3nmG8Svybq72Ki7eW0cg7ScOpO_BQIrWg-KWz1FLq5yJQ3YMnyXdNj3Bw&_hsmi=381912454&utm_content=381826388&utm_source=hs_email Global emergence and transmission dynamics of carbapenemase-producing Citrobacter freundii sequence type 22 high-risk international clone: a retrospective, genomic, epidemiological study https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00077-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanmic&utm_campaign=update-lanmic&utm_medium=email&_hsenc=p2ANqtz-8MExjZOguAgjcvJimPjIPalSgVmBqdgUQSNJIJUJF0RVv_VMkbaO1chCLnHVKqBtAB-XLVTwPYp16NpHUHbODffFl_oA&_hsmi=381912454&utm_content=381826388&utm_source=hs_email

Editorial p813 What is the hidden cost of expensive drugs? The Lancet Diabetes & Endocrinology +...

Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00164-0/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-9aszf7nJTvnE0RX4TnVOgIbkW437IydF0ZMnn-Nb-y4vf18PdYWLebezL4KtUPB2NqnC6Pkki4v0_zIv5YtB-00mKqjQ&_hsmi=381907503&utm_content=381684970&utm_source=hs_email Editorial p813 What is the hidden cost of expensive drugs? The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/issue/vol13no10/PIIS2213-8587(25)X0010-3 Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00165-2/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-92X7XrAn8rQEk7uWF02GPkzPvKtgTgi9o_zMjTUHy_EkWtoXxXd75GlPMRy5aQ7ulvLkMT2t_XfaylIwZ1N8_wz10wQg&_hsmi=381907503&utm_content=381684970&utm_source=hs_email The central role of recovery of β-cell function in the remission of prediabetes: a prospective cohort study in Canada https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00163-9/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz--Uu6vhQHmNE9T9bjGws2k3TW6KK91aNMhAuECfkRjcM86Lo9g5MbGiLQ9FlchbJyyHkw0py8JMDSZVLPKg3-P4Hy6wAw&_hsmi=381907503&utm_content=381684970&utm_source=hs_email

How stories, data and relationships impact decision-making in mental health - IAMHRF Online Symposium: Hearts and minds, inspired by The Lancet Psychiatry’s Commission on Transforming Mental Health Implementation Research. Oct 22, 2025, 2:00 PM BST / 9:00 AM ET.

https://iamhrf.org/events/how-stories-data-and-relationships-impact-decision-making-in-mental-health/?utm_campaign=infocusalerts-psychiatry&utm_medium=email&_hsenc=p2ANqtz-_H8RHMUflZkBCcQIhEaUknAkYg04GY-PdbDqgROBvtFpqD4a-JrRTiZb8lNLWR6KqUgtnCmt-UuOsevxzqrD-FKmQmMA&_hsmi=382565058&utm_content=382450884&utm_source=hs_email

FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast

AACR Sees Big Wins and Lagging Progress in Fight Against Cancer Sharon Worcester September 29, 2025

https://www.medscape.com/viewarticle/aacr-sees-big-wins-and-lagging-progress-fight-against-cancer-2025a1000q06

Woman With Synchronous Breast and Rectal Cancers and HBV Flare Wolfgang Paik Medscape UK September 29, 2025

https://www.medscape.com/viewarticle/woman-synchronous-breast-and-rectal-cancers-and-hbv-flare-2025a1000pzv

Raising the Bar on Breast Cancer Screening and Management Authors: Stamatia V. Destounis, MD, FACR, FSBI, FAIUM; Heather I. Greenwood, MD; Linda Moy, MD; Sarah Eskreis-Winkler, MD, PhD

https://www.medscape.org/viewarticle/raising-bar-breast-cancer-screening-and-management-2025a1000jjj?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_250928-OUS-HONC-raising-bar-breast-cancer-screening-and-management-2025a1000jjj-cta

domingo, 28 de septiembre de 2025

Batten disease hits the gut, but gene therapy may help A gene therapy targeting organs beyond the brain could improve quality of life and possibly extend survival in children with the neurodegenerative disease.

https://www.drugdiscoverynews.com/batten-disease-hits-the-gut-but-gene-therapy-may-help-16297?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9rZO5vKUjIUPupVQLsg-Vyl4zS-Z-JWjPtbc4ff2rOCR1-2Ym5AKUGVphr8K7Yj0RN44TTBxSapwZKijMjTwBF54N2hg&_hsmi=382421970&utm_content=382421970&utm_source=hs_email

First brain-delivered AAV therapy approved by FDA The gene therapy treats the rare genetic disease AADC deficiency by delivering a functional gene into the brain.

https://www.drugdiscoverynews.com/first-brain-delivered-aav-therapy-approved-by-fda-16214?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9zvfPLFVCUgoktj5NuAZYyUgeWjIwIDx8UMh8woVe1sNQdPQjRnXADT9y-nojgZpKdZQAho1sDlgjm6tfmve090BuvFQ&_hsmi=382421970&utm_content=382421970&utm_source=hs_email

KRAS-targeted cancer vaccine shows promise Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.

https://www.drugdiscoverynews.com/kras-targeted-vaccine-shows-promise-16685

Weekly Rundown: Huntington's disease slowed in gene therapy trial Promising new therapies for Huntington’s disease and multiple myeloma, the first FDA approval for Barth syndrome, and more led the news this week.

https://www.drugdiscoverynews.com/weekly-rundown-huntington-s-disease-slowed-in-gene-therapy-trial-16689

FDA Approves New Treatment for Acromegaly, a Rare Endocrine Disorder

https://content.govdelivery.com/accounts/USFDA/bulletins/3f47b78 FDA Approves New Treatment for Acromegaly, a Rare Endocrine Disorder Action The U.S. Food and Drug Administration (FDA) approved Palsonify (paltusotine) tablets to treat adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Disease or Condition Acromegaly is a rare endocrine disorder that causes some bones, organs, and other tissue to grow bigger. The pituitary gland in the brain causes these changes by making too much growth hormone (GH) due to the presence of a non-cancerous tumor. Effectiveness Palsonify’s safety and efficacy was evaluated in 2 randomized, double-blind, placebo‑controlled, phase 3 studies. In Study 1, 111 adults with acromegaly received Palsonify or placebo. The primary endpoint was the proportion of participants achieving biochemical control (defined as insulin-like growth factor [IGF-1] and GH levels within the normal range). At 24 weeks, 56% of participants who received Palsonify had achieved biochemical control compared to 5% of participants who had received placebo. In Study 2, 58 adults with acromegaly who were previously treated with and responded to other medical therapy received Palsonify or placebo. At 36 weeks, 83% of participants switching to Palsonify in Study 2 maintained biochemical control compared to 4% of participants receiving placebo. Safety Information Palsonify increases the risk of cholelithiasis (gallstones); hyperglycemia (high blood sugar); hypoglycemia (low blood sugar); bradycardia (low heart rate); thyroid function abnormalities; steatorrhea (excessive fat in the stool) and malabsorption of dietary fats; and changes in vitamin B12 levels. The most common side effects are diarrhea, abdominal pain, nausea, decreased appetite, bradycardia, hyperglycemia, and gastroenteritis (stomach inflammation). Dosing and Administration The recommended initial dosage is 40 mg taken orally once daily with water on an empty stomach, at least 6 hours after a meal (i.e., after overnight fasting) and at least 1 hour before the next meal. During the initiation period, Palsonify may be temporarily reduced to 20 mg once daily if needed, based on tolerability. Once adverse reactions have resolved, patients should resume Palsonify 40 mg once daily. After 2 to 4 weeks on Palsonify 40 mg once daily and based on their IGF-1 levels, patients may be advised to increase the dosage to 60 mg once daily.

FDA Focuses on Closing the Clinical Trial Reporting Gap for Research Integrity

https://www.fda.gov/news-events/fda-voices/fda-focuses-closing-clinical-trial-reporting-gap-research-integrity?utm_medium=email&utm_source=govdelivery FDA Focuses on Closing the Clinical Trial Reporting Gap for Research Integrity Clinical trial transparency is fundamental to maintaining public trust in medical research and supports broader scientific advancements among the global clinical research community. The U.S. Food and Drug Administration is keenly focused on clinical trial transparency, which is an ethical obligation under the Declaration of Helsinki and rooted in the fundamental principles of medical research. The Declaration of Helsinki establishes ethical principles for medical research involving human subjects and serves as a cornerstone document for the international medical community, providing guidance on issues such as informed consent and the protection of vulnerable populations in clinical trials. This declaration emphasizes that data transparency is essential for enabling scientific advancements and protecting research participants' rights and well-being.

Biomarkers, Genetics, and Anti-Amyloid Therapies for Early Stages of AD Authors: Douglas R. Galasko, MD; Lon Schneider, MD, MS

https://www.medscape.org/viewarticle/1002844_sidebar10?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_250926-1002844_ES_NEUR

Monitoring ESR1 ctDNA During First-Line Care of HR-Positive Advanced Breast Cancer: A New Approach Authors: François-Clément Bidard, MD, PhD; Nicola Fusco, MD, PhD

https://www.medscape.org/viewarticle/1002782?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_250926-OUS-HONC-1002782-cta

Highlights From the Annual Oncology Meeting: Clinical Integration of Therapeutic Innovations in Glioma Authors: Matthias Preusser, MD; Manmeet S. Ahluwalia, MD, MBA, FASCO; L. Nicolas Gonzalez Castro, MD, PhD; Jeremy Pivor

https://www.medscape.org/viewarticle/1002677?sso=true&uac=148436CN&src=mkmcmr_driv_32025_mscpedu_421033.16_ace_launch

Addressing Challenges for Patients With HR+/HER2- EBC: Managing AEs and Optimizing Adherence Authors: Sarah Donahue, MPH, NP, AOCNP; Erika Hamilton, MD; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/1002936?sso=true&impID=7752551&uac=148436CN&src=wnl_tpal_250926_mscpedu

Hormone Receptor-Positive Metastatic Breast Cancer: Novel Endocrine-Based Strategies and Options After Progression Authors: Volkmar Müller, MD; Erica L. Mayer, MD, MPH

https://www.medscape.org/viewarticle/1002835_sidebar11?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_250927-1002835-ES_LANG-HONC

Explore our latest GBD Studies, related content, and more ++++++

The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01635-6/abstract?utm_campaign=gbdalerts&utm_medium=email&dgcid=hubspot_email_lancet-gbdalerts&_hsenc=p2ANqtz-9LHv1sTiI3Fei5TTxh8MjstpB-12A2ALJQXxLqA84PL0Jm1whoGUyXrk4N_TZA6cRv4_B3D7LQD8NQwjBePDaZ3wdU1A&_hsmi=382482578&utm_content=382452519&utm_source=hs_email Global, regional, and national cascades of diabetes care, 2000–23: a systematic review and modelling analysis using findings from the Global Burden of Disease Study https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00217-7/abstract?utm_campaign=gbdalerts&utm_medium=email&dgcid=hubspot_email_lancet-gbdalerts&_hsenc=p2ANqtz--KQ6gLwEv-DzyKg4NBExXY4J21Mw3lEM43H6FAQfMWyKNG6pHbY7pQvBMotg7TN4DugckCCd_Dx71IvfU2NIhpt6Qbdg&_hsmi=382482578&utm_content=382452519&utm_source=hs_email Tracking development assistance for health, 1990–2030: historical trends, recent cuts, and outlook https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01240-1/abstract?utm_campaign=gbdalerts&utm_medium=email&dgcid=hubspot_email_lancet-gbdalerts&_hsenc=p2ANqtz-9V_utl0uQibZSY7EEhqYyLD2bKKV8lqwqjyRHicDU8TlNggk5L0hqbGzmLiv5k_MJnGd8Qcp531ZE4VIJVZaZ4ecs0kQ&_hsmi=382482578&utm_content=382452519&utm_source=hs_email Global, regional, and national health-care inefficiency and associated factors in 201 countries, 1995–2022: a stochastic frontier meta-analysis for the Global Burden of Disease Study 2023 https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00178-0/fulltext?dgcid=hubspot_email_lancet-gbdalerts&utm_campaign=gbdalerts&utm_medium=email&_hsenc=p2ANqtz-8Fj2RyKHhV3IY3r0kkvySRaN8DEcMXDLLPjEvIIZY6HB1oNurVvFGEiGlQq_BRSDRw_vmSslV810WGyjYZklGDI-bF8A&_hsmi=382482578&utm_content=382452519&utm_source=hs_email Leveraging socioeconomic development for maternal health, breast cancer, and gynaecological cancers across 204 locations: a stochastic frontier analysis from the Global Burden of Disease Study 2023 https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(25)00031-7/abstract?utm_campaign=gbdalerts&utm_medium=email&dgcid=hubspot_email_lancet-gbdalerts&_hsenc=p2ANqtz-9G75tcnuP3F4PWAcZN1Y79NnOeOYunjSSzdle-3ggI0sMbClFL2by4pQ9GF3nuDgGMUPy1Jctqs-Y1a7QRBW0KmauTqA&_hsmi=382482578&utm_content=382452519&utm_source=hs_email Global burden of vision impairment due to age-related macular degeneration, 1990–2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021 https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00143-3/fulltext?dgcid=hubspot_email_lancet-gbdalerts&utm_campaign=gbdalerts&utm_medium=email&_hsenc=p2ANqtz-9QOl9e9zTDMRVJiqU08hcUEitdZd2GOx3uld5IoCitR9fi2-jg5b263ZRk3oB4-aV8-F8oSEqbCxpNNW-4bDuMeYeIDg&_hsmi=382482578&utm_content=382452519&utm_source=hs_email

Implementing the MASH Care Pathway in Endocrinology Practice Authors: Arun J. Sanyal, MD; Kenneth Cusi, MD, FACP, FACE

https://www.medscape.org/viewarticle/1002940?sso=true&impID=7754633&uac=148436CN&src=wnl_tpal_250927_mscpedu

1 IN 5: THE ALARMING RISE OF SUICIDAL THOUGHTS IN TEENS

1 In 5: The Alarming Rise Of Suicidal Thoughts In Teens By Ivanhoe Broadcast News on September 15, 2025 https://www.ivanhoe.com/family-health/children/1-in-5-the-alarming-rise-of-suicidal-thoughts-in-teens/

UNDER PRESSURE: THE TRUTH ABOUT TEEN STRESS

Under Pressure: The Truth About Teen Stress By Ivanhoe Broadcast News on September 24, 2025 https://www.ivanhoe.com/smart-living/under-pressure-the-truth-about-teen-stress/

QUIET HIRING WITHOUT A RAISE OR PROMOTION?

Quiet Hiring Without a Raise or Promotion? By Ivanhoe Broadcast News on September 29, 2025 https://www.ivanhoe.com/?p=36071&preview=1&_ppp=64e0e68996

RUNNING ON EMPTY: THE BURNOUT CRISIS IN KIDS

Running On Empty: The Burnout Crisis in Kids By Ivanhoe Broadcast News on September 30, 2025 https://www.ivanhoe.com/?p=36074&preview=1&_ppp=4293914076

SMALL BITE, BIG IMPACT: FIGHTING TICKS

Small Bite, Big Impact: Fighting Ticks By Ivanhoe Broadcast News on October 1, 2025 https://www.ivanhoe.com/?p=36086&preview=1&_ppp=639066f434

A FATHER’S FIGHT: FROM RELAPSE TO REMISSION

A Father’s Fight: From Relapse to Remission By Ivanhoe Broadcast News on October 2, 2025 https://www.ivanhoe.com/?p=36087&preview=1&_ppp=edd4e0dca6

ESD: REMOVING CANCER WITHOUT A SINGLE STITCH

ESD: Removing Cancer Without a Single Stitch By Ivanhoe Broadcast News on October 3, 2025 https://www.ivanhoe.com/?p=36088&preview=1&_ppp=1704b83374

sábado, 27 de septiembre de 2025

Dangerous spike in superbug infections surges across US as experts share cautions By Melissa Rudy Fox News Published September 24, 2025 3:47pm EDT

Dangerous spike in superbug infections surges across US as experts share cautions CDC warns NDM-CRE bacteria can be fatal and spreads quickly through communities Melissa Rudy By Melissa Rudy Fox News Published September 24, 2025 3:47pm EDT https://www.foxnews.com/health/dangerous-spike-superbug-infections-surges-across-us-experts-share-cautions

Eye drops may replace reading glasses for those struggling with age-related vision loss By Khloe Quill Fox News Published September 25, 2025 3:30pm EDT

Eye drops may replace reading glasses for those struggling with age-related vision loss Experimental medication could offer accessible alternative to reading glasses and surgical procedures By Khloe Quill Fox News Published September 25, 2025 3:30pm EDT https://www.foxnews.com/health/eye-drops-may-replace-reading-glasses-those-struggling-age-related-vision-loss

Weight-loss doctor shares how GLP-1s could rewire body against disease By Angelica Stabile Fox News Published September 25, 2025 7:00am EDT

Weight-loss doctor shares how GLP-1s could rewire body against disease Expert shares some surprising benefits of GLP-1s beyond the scale Angelica Stabile By Angelica Stabile Fox News Published September 25, 2025 7:00am EDT https://www.foxnews.com/health/weight-loss-doctor-shares-how-glp-1s-could-rewire-body-against-disease?lid=4oebo04sfjta

Four families are desperate to raise funds for their children’s paralyzing disease By Melissa Rudy Fox News Published September 22, 2025 7:00am EDT

Four families are desperate to raise funds for their children’s paralyzing disease Treatment for rare genetic disease awaits FDA approval as parents race to raise money for clinical trial Melissa Rudy By Melissa Rudy Fox News Published September 22, 2025 7:00am EDT https://www.foxnews.com/health/families-race-against-time-raise-funds-childrens-paralyzing-disease

No more injections? New pill could replace Ozempic and Wegovy for weight loss By Angelica Stabile Fox News Published September 23, 2025 6:20pm EDT

No more injections? New pill could replace Ozempic and Wegovy for weight loss Oral GLP-1 drug could get FDA approval by year's end, per reports Angelica Stabile By Angelica Stabile Fox News Published September 23, 2025 6:20pm EDT https://www.foxnews.com/health/no-more-injections-new-pill-could-replace-ozempic-wegovy-weight-loss

Blinded Army veteran who survived attack turns trauma into mission to help others By Ashley J. DiMella Fox News Published September 26, 2025 7:00am EDT

Blinded Army veteran who survived attack turns trauma into mission to help others After losing his vision, Jeffrey Mittman now helps create employment opportunities for disabled Americans Ashley J. DiMella By Ashley J. DiMella Fox News Published September 26, 2025 7:00am EDT https://www.foxnews.com/health/blinded-army-veteran-who-survived-attack-turns-trauma-mission-help-others

Cancer drug could double as autism therapy, and is poised for FDA approval By Melissa Rudy Fox News Published September 22, 2025 6:46pm EDT

Cancer drug could double as autism therapy, and is poised for FDA approval Health officials say leucovorin shows promise for improving communication skills in certain young patients Melissa Rudy By Melissa Rudy Fox News Published September 22, 2025 6:46pm EDT https://www.foxnews.com/health/cancer-drug-could-double-autism-therapy-poised-fda-approval-officials-say

Hidden causes of heart attacks often overlooked or misdiagnosed, study finds By Melissa Rudy Fox News Published September 23, 2025 3:14pm EDT

Hidden causes of heart attacks often overlooked or misdiagnosed, study finds Over half of cardiac events in women under 65 caused by nontraditional factors, researchers warn Melissa Rudy By Melissa Rudy Fox News Published September 23, 2025 3:14pm EDT https://www.foxnews.com/health/hidden-causes-heart-attacks-often-overlooked-misdiagnosed-study-finds

Autism by the numbers: Experts share reasons for the dramatic surge in diagnoses By Melissa Rudy Fox News Published September 24, 2025 7:00am EDT

Autism by the numbers: Experts share reasons for the dramatic surge in diagnoses Increase likely due to rising awareness plus environmental factors, doctors say Melissa Rudy By Melissa Rudy Fox News Published September 24, 2025 7:00am EDT https://www.foxnews.com/health/autism-numbers-experts-share-reasons-dramatic-surge-diagnoses

New virus strain spikes in 9 US states with symptoms from brain fog to persistent cough By Angelica Stabile Fox News Published September 25, 2025 11:28am EDT

New virus strain spikes in 9 US states with symptoms from brain fog to persistent cough Stratus COVID variant shows ability to evade immune system better than previous strains Angelica Stabile By Angelica Stabile Fox News Published September 25, 2025 11:28am EDT https://www.foxnews.com/health/new-virus-strain-spikes-us-states-symptoms-from-brain-fog-persistent-cough

Autism symptoms in adults and new virus surge, plus GLP-1 benefits By Fox News Staff Fox News Published September 26, 2025 3:34pm EDT

Autism symptoms in adults and new virus surge, plus GLP-1 benefits And more of the top Fox News Health stories and videos from the past week By Fox News Staff Fox News Published September 26, 2025 3:34pm EDT https://www.foxnews.com/health/autism-symptoms-adults-new-virus-surge-glp-1-benefits

Common vitamin shown to slash skin cancer risk in some groups, study suggests By Angelica Stabile Fox News Published September 26, 2025 6:13pm EDT

Common vitamin shown to slash skin cancer risk in some groups, study suggests Those taking the vitamin had 14% lower risk of the disease, researchers found Angelica Stabile By Angelica Stabile Fox News Published September 26, 2025 6:13pm EDT https://www.foxnews.com/health/common-vitamin-shown-slash-skin-cancer-risk-some-groups-study-suggests

Autism spectrum in adults has commonly overlooked symptoms, experts warn By Angelica Stabile Fox News Published September 23, 2025 7:00am EDT

Autism spectrum in adults has commonly overlooked symptoms, experts warn Some 5.4 million American adults are living with autism, but many go undiagnosed Angelica Stabile By Angelica Stabile Fox News Published September 23, 2025 7:00am EDT https://www.foxnews.com/health/autism-spectrum-adults-commonly-overlooked-symptoms-experts-warn?lid=irye6vhf8j4a

Updates to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV

https://www.hiv.gov/blog/updates-to-the-guidelines-for-the-use-of-antiretroviral-agents-in-adults-and-adolescents-with-hiv

Raising the Bar on Breast Cancer Screening and Management: A Medscape RadTech Activity Authors: Stamatia V. Destounis, MD, FACR, FSBI, FAIUM; Heather I. Greenwood, MD; Linda Moy, MD; Sarah Eskreis-Winkler, MD, PhD

https://www.medscape.org/viewarticle/raising-bar-breast-cancer-screening-and-management-medscape-2025a1000mqn?page=1

ECG Challenge: Uncontrolled Blood Pressure During Routine Exam Philip J. Podrid, MD September 25, 2025

https://www.medscape.com/viewarticle/ecg-challenge-uncontrolled-blood-pressure-during-routine-2025a1000p0k

Improving Cardiometabolic Health in Type 2 Diabetes Kevin Fernando, MBChB September 26, 2025

https://www.medscape.com/viewarticle/1002912

Sep 26, 2025 This Week in Cardiology Podcast John M. Mandrola, MD September 26, 2025

https://www.medscape.com/viewarticle/1002944

Vericiguat Is Not the VICTOR in Heart Failure Drug Competition Ileana L. Piña, MD, MPH; James L. Januzzi, MD September 26, 2025

https://www.medscape.com/viewarticle/vericiguat-not-victor-heart-failure-drug-competition-2025a1000onx

College of American Pathologists (CAP) 2025 September 13 - 16, 2025 | Orlando, Florida

https://www.medscape.com/viewcollection/37885?ecd=WNL_conf_CAP-path-NON-SPON_250927_MSCPEDIT_etid7746019&uac=148436CN&impID=7746019

viernes, 26 de septiembre de 2025

Tumor cells adapt and thrive in damaged parts of the pancreas

https://www.news-medical.net/news/20250926/Tumor-cells-adapt-and-thrive-in-damaged-parts-of-the-pancreas.aspx

Emergency calls for opioid exposures rise among middle-school aged children

https://www.news-medical.net/news/20250926/Emergency-calls-for-opioid-exposures-rise-among-middle-school-aged-children.aspx

Breakthrough in predicting Parkinson’s and dementia in people with REM sleep behavior disorder

https://www.news-medical.net/news/20250926/Breakthrough-in-predicting-Parkinsone28099s-and-dementia-in-people-with-REM-sleep-behavior-disorder.aspx

eBook: Proteomics and Integral Proteomics Insights

https://www.news-medical.net/industry-focus/eBook-Proteomics?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=immunology_newsletter_24_september_2025&utm_form_handler=qw599t

FIND YOUR WAY TO QUALITY ALCOHOL TREATMENT +...

FIND YOUR WAY TO QUALITY ALCOHOL TREATMENT In addition to in-person options, you can access alcohol treatment through telehealth services and other online options. Learn how to find quality care https://alcoholtreatment.niaaa.nih.gov/

What is pain? + +...

https://www.ninds.nih.gov/health-information/disorders/pain Pain is an unpleasant sensory and emotional experience. Health Highlights https://www.nih.gov/health-information

Anxiety Disorders + +...

https://www.nimh.nih.gov/health/topics/anxiety-disorders Health Highlights https://www.nih.gov/health-information

Urban design affects walking levels + +...

https://www.nih.gov/news-events/nih-research-matters/urban-design-affects-walking-levels At a Glance A large study using smartphone data found that moving to different communities can affect how much you walk. The results suggest that the design of a community can play a role in levels of physical activity. Health Highlights https://www.nih.gov/health-information

Probing Aspirin’s Benefits Exploring its Role in Prevention + +...

https://newsinhealth.nih.gov/2025/09/probing-aspirin-s-benefits Health Highlights https://www.nih.gov/health-information

Epilepsy Undertreatment and Overtreatment: How Can We Strike a Balance? Authors: Marian Galovic, MD, PhD; Bernhard J. Steinhoff, MD, PhD; Rhys H. Thomas, MBChB, BSc, MSc, PhD, FRCP

https://www.medscape.org/viewarticle/1002731_sidebar9?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_250925-1002731_ES_NEUR

FDA Removes Risk Evaluation and Mitigation Strategies (REMS) for Caprelsa (vandetanib) Agency determines special restrictions are no longer necessary to ensure the benefits of thyroid cancer treatment with Caprelsa outweigh its risks

https://www.fda.gov/news-events/press-announcements/fda-removes-risk-evaluation-and-mitigation-strategies-rems-caprelsa-vandetanib?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration today removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Genzyme Corporation (now Sanofi). The FDA first approved Caprelsa in 2011 to treat medullary thyroid cancer in patients whose disease has spread or cannot be surgically removed. At the time, a REMS program was required to ensure appropriate heart rhythm monitoring and safe use. After over more than a decade of oversight, REMS assessments reported no cases of Torsades de pointes or unexplained sudden deaths among U.S. patients taking Caprelsa. Clinical data also showed no concerning patterns of heart rhythm problems. “Cancer specialists now have adequate knowledge about managing the heart rhythm related risks of this medication,” said Richard Pazdur, M.D., FDA Oncology Center of Excellence Director. “Health care providers have incorporated proper safety monitoring into their standard practice, making the formal requirements unnecessary. The mandatory monitoring program has achieved its goals.” Caprelsa will remain available with the same prescribing information, but health care providers will no longer need special certification or extra monitoring beyond standard clinical care. A REMS is a safety program that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. The safety requirements for Caprelsa included mandatory training for health care providers and monitoring of patients. Contact Information: Health care providers, pharmacies, and patients with questions may contact the FDA at (855) 543-3784 or (301) 796-3400, or by email at druginfo@fda.hhs.gov. Adverse events, medication errors, or quality problems with Caprelsa should be reported to FDA's MedWatch Adverse Event Reporting program. FDA's top priority is patient safety, and the agency will continue to monitor the safety of this medication.

Advancing Patient-Centered Care in mCRPC: Exploring PARP Inhibitor Combinations Authors: Neeraj Agarwal, MD, FASCO; Karim Fizazi, MD, PhD

https://www.medscape.org/viewarticle/1002353?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_250925-OUS-HONC-1002353-cta

FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast

Most Read Papers - Cancer Science & Oncogenesis +...

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_250926

Approval of New Patch Tests for the Diagnosis of Allergic Contact Dermatitis; Public Workshop October 23, 2025

https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/approval-new-patch-tests-diagnosis-allergic-contact-dermatitis-public-workshop-10232025?utm_medium=email&utm_source=govdelivery

FDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia

https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-eyeglass-lenses-slow-progression-pediatric-myopia?utm_medium=email&utm_source=govdelivery Today, the U.S. Food and Drug Administration authorized marketing of the Essilor Stellest eyeglass lenses to correct myopia, commonly referred to as nearsightedness, with or without astigmatism and to slow the progression of the disease in children 6 to 12 years old at the initiation of treatment. Strengthening the foundation of our nation’s health begins at childhood. This authorization reflects the FDA’s unwavering commitment to addressing chronic diseases and advancing safe, effective, and innovative medical devices that improve the lives of young Americans. “As a practicing ophthalmologist, I see firsthand the lifelong impact that vision problems can have on an individual. Today’s authorization brings to market a treatment option that may meaningfully reduce the likelihood of severe eyesight issues later in adult life, while also being easier to use and lower risk than the currently authorized devices that slow the progression of myopia in children,” said Center for Devices and Radiological Health Director Michelle Tarver, M.D., Ph.D. According to the National Eye Institute, several studies indicate that the prevalence of myopia is increasing in the U.S. and worldwide, and researchers project the trend will continue in the coming decades. Myopia is a chronic disease that affects approximately 40% of the U.S. population, with prevalence increasing rapidly among children and adolescents. By 2050, it is estimated that more than 50% of the world population may become myopic. When left untreated, this disease can progress to high myopia, which can significantly increase risks of sight-threatening complications, including retinal detachment, myopic maculopathy, glaucoma, and cataracts later in life. Myopia typically progresses in school-aged children when their eyes are still growing, leveling off in early adulthood. Prior to Essilor Stellest eyeglass lenses, there was only one approved device for slowing the progression of myopia in the form of contact lenses, for 8 to 12-year-olds. The Essilor Stellest eyeglass lenses can fill the gap for children 6 to 7 years old or for children who are unable to wear contacts. These Essilor Stellest eyeglass lenses are a lower risk device compared to contact lenses and do not have adverse events (such as infections) that may be associated with the use of contact lenses. The Essilor Stellest eyeglass lenses have a clear 9mm diameter area in the center, which is surrounded by rings of tiny, raised dots (peripheral lenslets) on the rest of the lens. The tiny, raised dots provide peripheral light defocus, which may help to slow the progression of myopia in children. The FDA evaluated two-years of data from a clinical study that demonstrated the Essilor Stellest eyeglass lenses slowed myopia progression as compared to single vision control lenses. The study measured the change in glasses prescription (spherical equivalent refraction) and the change in the length of the eye (axial length). For spherical equivalent refraction, the study showed a 71% reduction in myopia progression at 24 months. For axial length, the study showed a 53% reduction in eye elongation at 24 months. There were no serious adverse events reported in the clinical study. However, some subjects did report visual symptoms, such as blur and halos, while wearing the Essilor Stellest eyeglass lenses. There are no labeled contraindications. The FDA reviewed the Essilor Stellest eyeglass lenses through the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this De Novo authorization, the FDA is establishing special controls that define the requirements related to labeling and performance testing. When met, the special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness for this device type. The FDA granted Breakthrough Device designation for the Essilor Stellest eyeglass lenses on April 30, 2021. A breakthrough designation is meant to expedite the development and review of devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The FDA granted marketing authorization of the Essilor Stellest lenses via the De Novo premarket review pathway to Essilor of America Inc.

Shaping the Future of Muscle-Invasive Bladder Cancer Care: Immunotherapy in Focus Authors: Andrea Necchi, MD; James W. F. Catto, MB, ChB, PhD, FRCS; Enrique Grande, MD, PhD

https://www.medscape.org/viewarticle/1002445?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_250926-OUS-HONC-1002445-cta

The 2025 EAT-Lancet Commission launches on October 3, 2025

The 2025 EAT-Lancet Commission launches on October 3, 2025 The 2025 EAT-Lancet Commission will publish its findings in The Lancet and officially launch at the Stockholm Food Forum. https://eatforum.org/learn-and-discover/2025-eat-lancet-commission-launch/?utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz--r7B65lcrSJfEUkJK5BQYOljBNj4mUjo0AA-O9CRKSoizrPOWaaaq6w1yKKw77fQa8u4MNtTTN6FpiqxrmmZuM7Jrn7g&_hsmi=381819639&utm_content=381819639&utm_source=hs_email Building on the landmark 2019 EAT-Lancet report, this new Commission provides an updated review of what constitutes a healthy, sustainable, and just food system in the context of today’s scientific, social, and environmental realities. It also draws on new evidence in the fields of dietary health, food systems’ impact on planetary boundaries, agricultural and livestock practices, economic modelling, and social justice.

Editorial p1313 Alzheimer's disease: are health systems ready? The Lancet + +... + +

Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01674-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd25&_hsenc=p2ANqtz-9IfOZivVoVHNjCDEAqYSvNcZvUT7rxu8VxDF8o2jcPPvFAExWs7WUkMYBJNcvJp_URmYcWgUHOx9Mq945ECLrA5HUysg&_hsmi=380999764&utm_content=380999764&utm_source=hs_email Editorial p1313 Alzheimer's disease: are health systems ready? The Lancet https://www.thelancet.com/journals/lancet/issue/vol406no10510/PIIS0140-6736(25)X0039-8 Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01774-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd25&_hsenc=p2ANqtz--gyptOL7plzIOKloLxVIQ6570RPyvxVA2d1fZbE37Ww2U6j-S4NMhyO5_T6zfiFjXnnAG2-6oUBmGuTr6Tv4B8bsZbNw&_hsmi=380999764&utm_content=380999764&utm_source=hs_email ATG as disease-modifying therapy for new-onset type 1 diabetes https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01773-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_easd25&_hsenc=p2ANqtz-_osuH1TFREfd7X9Klr2q4U0oifDnt4yFgGmaWFraBZMDIBBpF8KHUkV4A6hemIY9QKuFtr-hzT0s13sHrIMhxi4LClSw&_hsmi=380999764&utm_content=380999764&utm_source=hs_email

World Conference on Lung Cancer (WCLC) 2025 September 06 - 09, 2025 | Barcelona, Spain and Virtual/Online

https://www.medscape.com/viewcollection/37881?ecd=WNL_conf_WCLC-onc-SPON_250926_MSCPEDIT_etid7745400&uac=148436CN&impID=7745400

jueves, 25 de septiembre de 2025

Greek yogurt after exercise lowers inflammation more than carbs

https://www.news-medical.net/news/20250925/Greek-yogurt-after-exercise-lowers-inflammation-more-than-carbs.aspx Researchers discovered that young men who ate Greek yogurt after training showed lower levels of inflammation than those who consumed a carb pudding, highlighting the power of fermented dairy in recovery.

Academia Drug Development and Pharmacotherapy: a new scientific translational journal focused on personalized therapy Federico Pea* [1,2]

https://www.academia.edu/academia-drug-development-and-pharmacotherapy/1/1/10.20935/AcadDrug7906 Academia.edu is launching a new scientific journal in the field of drug development and pharmacotherapy. This will be a translational journal focused on all the different aspects which, from bench to bedside, may enable maximizing the likelihood of providing more effective and safe pharmacotherapy in the era of precision medicine.

Artificial Intelligence and Infectious Diseases + + +...

https://www.thelancet.com/series-do/artificial-intelligence-and-infectious-diseases?dgcid=raven_jbs_etoc_feature_laninfaiandid25 More data needed on the FDA's decision to suspend Ixchiq The Lancet Infectious Diseases https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00552-3/fulltext?dgcid=raven_jbs_etoc_email Oct 2025 Volume 25Number 10p1055-1158, e542-e620 https://www.thelancet.com/journals/laninf/issue/vol25no10/PIIS1473-3099(25)X0010-4

Chemophobic misinformation: 40% of Europeans say they ‘want to live in a world where chemicals don’t exist’ Richard Williams | Fixing Food | September 24, 2025

https://geneticliteracyproject.org/2025/09/24/chemophobic-misinformation-40-of-europeans-say-they-want-to-live-in-a-world-where-chemicals-dont-exist/

Video: Should we revamp our diet to eat mostly organic foods? Harvard gastroenterologist says fears are based on hysteria not science Hindustan Times | September 25, 2025

https://geneticliteracyproject.org/2025/09/25/video-should-we-revamp-our-diet-to-eat-mostly-organic-foods-harvard-gastroenterologist-says-fears-are-based-on-hysteria-not-science/

Can devout Muslims or Jews receive organ transplants from genetically-altered pigs? Roni Caryn Rabin | New York Times | September 25, 2025

https://geneticliteracyproject.org/2025/09/25/can-devout-muslims-or-jews-receive-organ-transplants-from-genetically-altered-pigs/

Biotechnology is pushing the limits of beauty products Britney Muoghalu | Style Rave | September 24, 2025

https://geneticliteracyproject.org/2025/09/24/biotechnology-is-pushing-the-limits-of-beauty-products/

New AI tool can predict each person’s risk for more than 1,000 diseases Andrew Gregory | Guardian | September 24, 2025

https://geneticliteracyproject.org/2025/09/24/new-ai-tool-can-predict-each-persons-risk-for-more-than-1000-diseases/

What is leucovorin, the drug RFK, Jr. and Dr. Oz claim could arrest autism? Alice Park | Time | September 25, 2025

https://geneticliteracyproject.org/2025/09/25/what-is-leucovorin-the-drug-rfk-jr-and-dr-oz-claim-could-arrest-autism/

Are human’s 5 senses the optimal number to interpret the world or might evolution provide better tools over time? Darren Orf | Popular Mechanics | September 25, 2025

https://geneticliteracyproject.org/2025/09/25/are-humans-5-senses-the-optimal-number-to-interpret-the-world-or-might-evolution-provide-better-tools-over-time/

GLP podcast: Spread meat allergy with gene-edited ticks? Bioethicists pose vile ‘thought experiment’ Cameron English, Liza Lockwood | September 25, 2025

https://geneticliteracyproject.org/2025/09/25/glp-podcast-spread-meat-allergy-with-gene-edited-ticks-bioethists-pose-vile-thought-experiment/

Two-step HIV vaccine approach sparks hope for better protection A new vaccination schedule pumps up the immune response to human immunodeficiency virus, overcoming a barrier that has frustrated vaccine designers.

https://www.drugdiscoverynews.com/two-step-hiv-vaccine-approach-sparks-hope-for-better-protection-16144?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8Y1deVbMgSF-r0XbB3CnxvKuhMZl-YA_34GKI3Jj7KjPE_SmsPwAzwcLJwlsMYK0AOa-RBQTUJ0Zfna2_2eYh9BNuZGg&_hsmi=382247589&utm_content=382247589&utm_source=hs_email

Targeting solid tumors two ways with one cancer vaccine IO Biotech’s two-pronged cancer vaccine targets tumors and the suppressive immune cells around them, demonstrating promising results in metastatic melanoma.

https://www.drugdiscoverynews.com/targeting-solid-tumors-two-ways-with-one-cancer-vaccine-16397?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-87MzVaAl8w9njyXrUU1J7JWNfwxQ6LxKvfiJsoV7U4cxJ3Xb34HuQ6SYyL1GavW5dEFTGwB5c2apUGZImP-eo291sGAg&_hsmi=382247589&utm_content=382247589&utm_source=hs_email

KRAS-targeted cancer vaccine shows promise Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.

https://www.drugdiscoverynews.com/kras-targeted-vaccine-shows-promise-16685?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9Bq7rVfKUDz8idJlzURxTgq0bzgNW3_5jtnvjeGXokjmm9S4ry8X9MmD-o7l5XUawcYQLSBs_PzUy6JQ4KsEzy2pOQlA&_hsmi=382247589&utm_content=382247589&utm_source=hs_email

Antibody-Drug Conjugates in Practice: Contemporary Questions for the Treatment of Metastatic Breast Cancer Authors: Judy King, MRCP, PhD; Giuseppe Curigliano, MD, PhD; Peter Schmid, MD, PhD, FRCP

https://www.medscape.org/viewarticle/1002851_sidebar11?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_250924-1002851-ES_LANG-HONC

Monitoring ESR1 ctDNA During First-Line Care of HR-Positive Advanced Breast Cancer: A New Approach Authors: François-Clément Bidard, MD, PhD; Nicola Fusco, MD, PhD

https://www.medscape.org/viewarticle/1002782?sso=true&uac=148436CN&src=mkmcmr_reeng_recap_mscpedu_activity Monitoring ESR1 ctDNA During First-Line Care of HR-Positive Advanced Breast Cancer: A New Approach Below are some key learning points to help reinforce the impact of this activity. ☑ ESR1 mutations • Are rare in untreated HR+ advanced/metastatic breast cancer and mostly arise under the pressure of therapy with aromatase inhibitors • They can be characterized by interpatient heterogeneity (different mutations arise in different patients), as well as intrapatient heterogeneity (different mutations arise in different metastatic sites) • These types of heterogeneities make ctDNA assessment as a superior method compared with solid biopsy samples ☑ Currently, ESR1 mutations are assessed on progression following first-line therapy in patients with HR+ advanced/metastatic breast cancer, and if detected, are targeted by treatment • However, ESR1 mutations can arise prior to detection of clinical progression • An emerging paradigm proposes monitoring for ESR1 mutations during first-line therapy, and if detected prior to clinical progression, therapy should be changed to a different regimen • Data supporting this approach are based on the positive results from PADA-1 (switch from exemestane + palbociclib to fulvestrant + palbociclib) and SERENA-6 (switch from an aromatase inhibitor + CDK4/6 inhibition to camizestrant + CDK4/6 inhibition), both of which showed significantly improved PFS following the switch compared to continuation regimen ☑ Practical considerations for ESR1 mutation monitoring: • Using ctDNA has several advantages: noninvasive sampling, potential for serial testing, captures tumor heterogeneity, potential for real-time monitoring • Only ddPCR and NGS offer the required sensitivity • The optimal moment for starting ESR1 monitoring and interval between tests during first-line therapy has not been established: clinical trials used 2-3 months, but perhaps a more relaxed interval can be employed • Standardization of laboratory and assessment protocols will be needed for practical implementation • However, the new monitoring paradigm can add additional testing burden as well as increased costs ☑ Multidisciplinary team education is needed for practical implementation of ESR1 mutation monitoring • Medical oncologist: need to understand when to test and what to do with the results • Pathologists and laboratory staff require training for testing methods and utility of results • Nurses are involved in sample collection and patient education

Vitamin B12 Cuts Risk for Chemotherapy Hand-Foot Syndrome Kathleen Doheny September 25, 2025

https://www.medscape.com/viewarticle/vitamin-b12-cuts-risk-chemotherapy-hand-foot-syndrome-2025a1000pns

Chemoradiotherapy Boosts Survival in High-Risk Endometrial Cancer Edited by Gargi Mukherjee September 25, 2025

https://www.medscape.com/viewarticle/chemoradiotherapy-boosts-survival-high-risk-endometrial-2025a1000pof

Patient-Centered Paroxysmal Nocturnal Hemoglobinuria Treatment and the Role of Terminal Complement Inhibitors Authors: Regis Peffault de Latour, MD, PhD; Talha Munir, MBChB, PhD; Rachel Paine; Richard Kelly, MBChB, PhD; Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath

https://www.medscape.org/viewarticle/1002332?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_250924-OUS-HONC-1002332-cta

Journal Club: Latest Advances in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Authors: Claudia Sommer, MD; Jeffrey Allen, MD; Anna Kostera-Pruszczyk, MD, PhD

https://www.medscape.org/viewarticle/1002373_sidebar11?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_250925-ES_LANG-NEUR-1002373-cta

Comprehensive and Personalized Approach to Managing mHSPC: Fitting the Right Pieces for Each Patient Authors: Fred Saad, MD, FRCS; Elena Castro, MD, PhD

https://www.medscape.org/viewarticle/1002043_sidebar7?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_250925-ES_LANG-HONC-1002043-cta

miércoles, 24 de septiembre de 2025

New recommendations aim to identify children with familial hypercholesterolemia

https://www.news-medical.net/news/20250923/New-recommendations-aim-to-identify-children-with-familial-hypercholesterolemia.aspx

WHO releases statement on acetaminophen use during pregnancy and autism

https://www.news-medical.net/news/20250924/WHO-releases-statement-on-acetaminophen-use-during-pregnancy-and-autism.aspx

High levels of albumin in the urine linked to increased risk of dementia

https://www.news-medical.net/news/20250924/High-levels-of-albumin-in-the-urine-linked-to-increased-risk-of-dementia.aspx

FAU study explores how a new drug may help treat PTSD and its common companions

https://www.news-medical.net/news/20250924/FAU-study-explores-how-a-new-drug-may-help-treat-PTSD-and-its-common-companions.aspx

New diagnostic methods and treatments needed to fight against Alzheimer's disease

https://www.news-medical.net/news/20250924/New-diagnostic-methods-and-treatments-needed-to-fight-against-Alzheimers-disease.aspx

Academia Drug Development and Pharmacotherapy: a new scientific translational journal focused on personalized therapy Federico Pea* [1,2]

Multiple Myeloma: Novel Quad Regimen Eases Toxicity Nancy A. Melville September 24, 2025

https://www.medscape.com/viewarticle/multiple-myeloma-novel-quad-regimen-eases-toxicity-2025a1000phm

New and Improved Postmastectomy RT Guideline Released M. Alexander Otto, PA, MMSc September 23, 2025

https://www.medscape.com/viewarticle/new-and-improved-postmastectomy-rt-guideline-released-2025a1000pf5

Oral Microbes Tied to Pancreatic Cancer Risk Frederik Joelving September 24, 2025

https://www.medscape.com/viewarticle/oral-microbes-tied-pancreatic-cancer-risk-2025a1000php

Underwater Mucosal Resection Better for Early Gastric Cancer Edited by Archita Rai September 24, 2025

https://www.medscape.com/viewarticle/underwater-mucosal-resection-better-early-gastric-cancer-2025a1000piz

Low-Dose Radiation Therapy Making a Comeback for Osteoarthritis Tara Haelle September 24, 2025

https://www.medscape.com/viewarticle/low-dose-radiation-therapy-making-comeback-osteoarthritis-2025a1000pj9

Poultry Consumption Linked to Long-Term Health Outcomes Edited by Patricia McKnight September 24, 2025

https://www.medscape.com/s/viewarticle/poultry-consumption-linked-long-term-health-outcomes-2025a1000ov7

Expert Interview: Best Practices for Extensive-Stage Small Cell Lung Cancer Care Authors: Jacob Sands, MD

https://www.medscape.org/viewarticle/expert-interview-best-practices-extensive-stage-small-cell-2025a1000of5?page=1

Raising the Bar on Breast Cancer Screening and Management

https://www.medscape.org/viewarticle/raising-bar-breast-cancer-screening-and-management-2025a1000jjj?page=1%3Fsrc%3Dmkmcmr_driv_32025_mscpedu_421597.09_ace_launch&uac=148436CN&sso=true

My unexpected journey: life with a rare liver tumour 24 September 2025

https://rarerevolutionmagazine.com/my-unexpected-journey-life-with-a-rare-liver-tumour/

New eye drops treat age-related vision changes, no glasses needed A novel eye drop from LENZ Therapeutics represents the first time the FDA has approved aceclidine, a cholinergic agonist, in any drug.

https://www.drugdiscoverynews.com/new-eye-drops-treat-age-related-vision-changes-no-glasses-needed-16680

Male contraception could become the norm Men have long lacked reversible contraceptives, but new hormonal and non-hormonal methods in development could finally give them control over family planning.

https://www.drugdiscoverynews.com/male-contraception-could-become-the-norm-16684

Respiratory viruses may trigger dormant cancers

https://www.nih.gov/news-events/nih-research-matters/respiratory-viruses-may-trigger-dormant-cancers Cancer cells can break away from their original tumors and travel to different parts of the body. These disseminated cancer cells (DCCs) can then grow into new tumors.

Dietary fatty acids may lead to a severe form of asthma

https://www.nih.gov/news-events/nih-research-matters/dietary-fatty-acids-may-lead-severe-form-asthma Scientists found preliminary evidence that dietary changes could be a potential approach to prevent a severe form of asthma, called neutrophilic asthma.

Overactive immune responses in ME/CFS

https://www.nih.gov/news-events/nih-research-matters/overactive-immune-responses-mecfs Researchers found signs of overactive immune responses in people with myalgic encephalomyelitis/chronic fatigue syndrome, ME/CFS.

Benefits of treating opioid use disorder in county jails

https://www.nih.gov/news-events/nih-research-matters/benefits-treating-opioid-use-disorder-county-jails

Aging on GLP-1s: Risks vs Rewards +++ +++ +++ +

martes, 23 de septiembre de 2025

Male Fertility and the Microbiome: How Gut and Semen Bacteria Affect Sperm Health

https://www.news-medical.net/health/Male-Fertility-and-the-Microbiome-How-Gut-and-Semen-Bacteria-Affect-Sperm-Health.aspx

Mindfulness meditation may help treat people with depression and Internet gaming disorder

https://www.news-medical.net/news/20250923/Mindfulness-meditation-may-help-treat-people-with-depression-and-Internet-gaming-disorder.aspx

Monitoring ESR1 ctDNA During First-Line Care of HR-Positive Advanced Breast Cancer: A New Approach Authors: François-Clément Bidard, MD, PhD; Nicola Fusco, MD, PhD

https://www.medscape.org/viewarticle/1002782?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_250922-OUS-HONC-1002782-cta

Breast Cancer Care in 2025: Breakthroughs and Takeaways From Chicago Authors: Massimo Cristofanilli, MD, FACP; Giuseppe Curigliano, MD, PhD; Sherene Loi, MMBS (Hons), FRACP, PhD, FAHMS

https://www.medscape.org/viewarticle/1002644?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_250922-OUS-HONC-1002644-cta

Housing: a determinant of health and equity The Lancet Public Health + +... +

https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00229-4/fulltext?dgcid=raven_jbs_etoc_email Oct 2025 Volume 10Number 10e804-e889 https://www.thelancet.com/journals/lanpub/issue/vol10no10/PIIS2468-2667(25)X0010-4 Targeting alcohol use in high-risk population groups: a US microsimulation study of beverage-specific pricing policies https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00165-3/fulltext?dgcid=raven_jbs_etoc_feature_lanpub

Unscientific vaccine policy endangers vulnerable patients The Lancet Rheumatology + +... +

Unscientific vaccine policy endangers vulnerable patients The Lancet Rheumatology https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00262-0/fulltext?dgcid=raven_jbs_etoc_email Oct 2025 Volume 7Number 10e659-e746 https://www.thelancet.com/journals/lanrhe/issue/vol7no10/PIIS2665-9913(25)X0010-2 Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00071-2/abstract?dgcid=raven_jbs_etoc_feature_lanrhe

Come Fly with Me: Drosophila Intestinal Stem Cells as a Model for Epithelial Homeostasis and Disease + +...

https://www.liebertpub.com/doi/10.1177/15473287251375493?utm_campaign=3759405-MAL_AUTH_ALL&utm_medium=email&_hsenc=p2ANqtz-_BllJnqrwjpO3UfXJ5wncOmgByQt1wVh0jLhUAPzVont2LL9j3fTO1gOO9IV5vqkDi79YEQQlXqNmbODHC2jXS9vAMbQ&_hsmi=381683985&utm_content=381683985&utm_source=hs_email Stem Cells and Development https://home.liebertpub.com/publications/stem-cells-and-development/125

Additive Manufacturing and Mechanical Behaviors of Carbon–Kevlar Intralayer Hybrid Continuous Fiber Composite Corrugated Sandwich Structures + +...

https://www.liebertpub.com/doi/10.1177/23297662251377375?utm_campaign=3759405-MAL_AUTH_ALL&utm_medium=email&_hsenc=p2ANqtz--it9OyoowGYYfucPhkRcUkOUh9EauO7M23cBPff4z8iag2XV_ZurdhxCYoN5_UJSQ5HB-b5WsMYeKtHJCzFpnwR7kVcw&_hsmi=381683985&utm_content=381683985&utm_source=hs_email 3D Printing and Additive Manufacturing https://www.liebertpub.com/toc/3dp/12/4

Binding and Ligand Activation Driven Enrichment–Directed Evolution of SaCas9 gRNAs Improves Gene Editing Efficiency + +...

https://www.liebertpub.com/doi/10.1177/21593337251370553?utm_campaign=3759405-MAL_AUTH_ALL&utm_medium=email&_hsenc=p2ANqtz-8rAvckQ6-G4nOJryVbm0iQtzmCN4_40LArWM81iC0KIyumuReYI8pura8Dm0xCybuxybJ0a7CzR_UnM3sAj7cwaLmtww&_hsmi=381683985&utm_content=381683985&utm_source=hs_email Nucleic Acid Therapeutics https://home.liebertpub.com/publications/nucleic-acid-therapeutics/601

Electrically Triggered Fluorescein and Dexamethasone Release from Conducting Polymer Hydrogels + +...

https://www.liebertpub.com/doi/10.1177/19373341251373100?utm_campaign=3759405-MAL_AUTH_ALL&utm_medium=email&_hsenc=p2ANqtz-_e6H9ImNxEJoMPQ2KTHidTD74CG2vx2UhMzUIdkE4c7bsk1JcjGmsN0uNsGGR5RIga879f8zUo7hvHW0v8xUQBJo7orQ&_hsmi=381683985&utm_content=381683985&utm_source=hs_email Tissue Engineering Part A https://www.liebertpub.com/toc/tea/31/17-18

CRISPR-Cas9 Single Nucleotide Editing of Tuberous Sclerosis Complex 2 Gene in Mesenchymal Stem Cells + +...

https://www.liebertpub.com/doi/10.1177/25731599251367059?utm_campaign=3759405-MAL_AUTH_ALL&utm_medium=email&_hsenc=p2ANqtz-8SbBOXS2wz6Pr9n2EBNMf60Z0khlWTwyA7oxmFrOUi_XQoCtcGuXlLv7N4OqIBedL_bVMv7IUknO01ep6zGUTNWXMiBQ&_hsmi=381683985&utm_content=381683985&utm_source=hs_email The CRISPR Journal https://www.liebertpub.com/toc/crispr/8/4

Lentiviral Gene Delivery Rescues Ciliary Defects in Patient-Derived Airway Organoids from Primary Ciliary Dyskinesia + +...

https://www.liebertpub.com/doi/10.1177/10430342251378128?utm_campaign=3759405-MAL_AUTH_ALL&utm_medium=email&_hsenc=p2ANqtz-9FgslpL1krJ289Lb72rWgEemqTw8cfnEjUPmgNjvpeSD-ItKhXGEflaxPAwxI_n4Dn6sgVrAx3zfw66eYqrdodfZ7iJg&_hsmi=381683985&utm_content=381683985&utm_source=hs_email Human Gene Therapy https://home.liebertpub.com/publications/human-gene-therapy/19

Adjuvant vs Neoadjuvant Therapy for Resectable NSCLC Mark G. Kris, MD September 23, 2025

https://www.medscape.com/viewarticle/adjuvant-vs-neoadjuvant-therapy-resectable-nsclc-2025a1000mj3

Expanded Screening Marks Turning Point in Lung Cancer Ticiana Leal, MD September 23, 2025

https://www.medscape.com/viewarticle/expanded-screening-marks-turning-point-lung-cancer-2025a1000o53

Sleep Disorders in the Context of Comorbidities ++

Sleep Disorders in the Context of Comorbidities Sleep Apnea: A Hidden Cardiac Threat in Kids With Epilepsy https://www.medscape.com/viewarticle/sleep-apnea-hidden-cardiac-threat-children-epilepsy-2025a1000nac?ecd=mkm_ret_250923_mscpmrk-OUS_InFocus_etid7738702&uac=148436CN&impID=7738702 GI Disorders Linked With Sleep Problems https://www.medscape.com/viewarticle/gi-disorders-linked-sleep-problems-2025a1000mvf?ecd=mkm_ret_250923_mscpmrk-OUS_InFocus_etid7738702&uac=148436CN&impID=7738702

Adjunct & Novel Interventions: Lavender Oil May Ease Sleep? ++

Adjunct & Novel Interventions Lavender Oil May Ease Sleep and Anxiety After Brain Surgery https://www.medscape.com/viewarticle/lavender-oil-may-ease-sleep-and-anxiety-after-brain-surgery-2025a1000nwc?ecd=mkm_ret_250923_mscpmrk-OUS_InFocus_etid7738702&uac=148436CN&impID=7738702 Overweight and Waking Up Hungry: What to Tell Patients https://www.medscape.com/viewarticle/overweight-and-waking-hungry-what-tell-patients-2025a1000lem?ecd=mkm_ret_250923_mscpmrk-OUS_InFocus_etid7738702&uac=148436CN&impID=7738702

GLP-1s for Sleep Apnea: What They Can (and Can’t) Do Alison S. Kole, MD, MPH

https://www.medscape.com/viewarticle/glp-1s-sleep-apnea-what-they-can-and-cant-do-2025a1000mam?ecd=mkm_ret_250923_mscpmrk-OUS_InFocus_etid7738702&uac=148436CN&impID=7738702

CPAP Use Tied to Reduced Mortality in T2D and Sleep Apnea Edited by Manasi Talwadekar September 16, 2025

https://www.medscape.com/viewarticle/cpap-use-tied-reduced-mortality-t2d-and-sleep-apnea-2025a1000oiw?ecd=mkm_ret_250923_mscpmrk-OUS_InFocus_etid7738702&uac=148436CN&impID=7738702

FDA Takes Action to Make a Treatment Available for Autism Symptoms

https://www.fda.gov/news-events/press-announcements/fda-takes-action-make-treatment-available-autism-symptoms?utm_medium=email&utm_source=govdelivery US Food and Drug Administration FDA Takes Action to Make a Treatment Available for Autism Symptoms The U.S. Food and Drug Administration today initiated the approval of leucovorin calcium tablets for patients with cerebral folate deficiency (CFD), a neurological condition that affects folate (a vitamin essential for brain health) transport into the brain. Individuals with cerebral folate deficiency have been observed to have developmental delays with autistic features (e.g., challenges with social communication, sensory processing, and repetitive behaviors), seizures, and problems with movement and coordination. The FDA has conducted a systematic analysis of literature published between 2009-2024, including published case reports with patient-level information, as well as mechanistic data, and has determined that the information supports a finding that leucovorin calcium can help individuals suffering from CFD. "We have witnessed a tragic four-fold increase in autism over two decades,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Children are suffering and deserve access to potential treatments that have shown promise. We are using gold standard science and common sense to deliver for the American people.” The FDA is working with GSK, the innovator of Wellcovorin (leucovorin calcium), on a process to include the essential scientific information needed for the safe and effective use of these drug products for adults and pediatric patients with CFD. As the New Drug Application (NDA) holder for this medicine, GSK has preliminarily agreed to work with the FDA on this relabeling effort. “The FDA is collaborating with GSK to broaden the existing Wellcovorin label," said George Tidmarsh, M.D., Ph.D., Director of the FDA’s Center for Drug Evaluation and Research. “This effort reflects the FDA’s commitment to identify opportunities to repurpose drugs to treat chronic diseases. The FDA remains committed to finding and treating the root causes of autism.” CFD has also been reported in a broader patient population with neuropsychiatric symptoms, including autistic features, and detectable serum autoantibodies to the folate receptor alpha; however, there are limitations on the available data for the use of leucovorin in this population and additional studies are needed to assess safety and efficacy.

FDA Responds to Evidence of Possible Association Between Autism and Acetaminophen Use During Pregnancy

https://www.fda.gov/media/188843/download?attachment=&utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration today initiated the process for a label change for acetaminophen (Tylenol and similar products) to reflect evidence suggesting that the use of acetaminophen by pregnant women may be associated with an increased risk of neurological conditions such as autism and ADHD in children. The agency also issued a related letter alerting physicians nationwide. “The FDA is taking action to make parents and doctors aware of a considerable body of evidence about potential risks associated with acetaminophen,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Even with this body of evidence, the choice still belongs with parents. The precautionary principle may lead many to avoid using acetaminophen during pregnancy, especially since most low-grade fevers don’t require treatment. It remains reasonable, however, for pregnant women to use acetaminophen in certain scenarios.” Evidence in recent years has suggested a correlation between acetaminophen use during pregnancy and subsequent diagnosis of conditions like autism and ADHD. Multiple large-scale cohort studies, including the Nurses’ Health Study II and the Boston Birth Cohort, find this association. Some studies have described that the risk may be most pronounced when acetaminophen is taken chronically throughout pregnancy. https://pubmed.ncbi.nlm.nih.gov/30923825/ https://pubmed.ncbi.nlm.nih.gov/31664451/ It is important to note that while an association between acetaminophen and neurological conditions has been described in many studies, a causal relationship has not been established and there are contrary studies in the scientific literature. It is also noted that acetaminophen is the only over-the-counter drug approved for use to treat fevers during pregnancy, and high fevers in pregnant women can pose a risk to their children. Additionally, aspirin and ibuprofen have well-documented adverse impacts on the fetus.